Press-release for stocks for gilead sciences, inc.

entities : Gilead sciences, inc.

save search

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Published: 2022-06-24 (Crawled : 13:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 8.22% | O: 1.52% H: 0.0% C: 0.0%
chmp hiv positive drug

Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Published: 2022-06-23 (Crawled : 16:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 8.76% | O: 0.5% H: 0.0% C: 0.0%
hepcludex treatment hepatitis virus response

Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 14.3% | O: 1.34% H: 0.0% C: 0.0%
liver disease international

Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
Published: 2022-06-16 (Crawled : 11:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M

Health Technology

| -98.37% | O: 0.45% H: 0.0% C: -3.6%
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 14.57% | O: -1.25% H: 0.82% C: 0.1%
pharma services commercialization

Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-06-10 (Crawled : 04:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 7.4% | O: -2.99% H: 0.0% C: 0.0%
trodelvy approval china cancer breast cancer

Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin (LYN-163) as a Tool in the Fight to Eradicate Malaria
Published: 2022-06-09 (Crawled : 14:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 7.25% | O: -0.14% H: 0.0% C: 0.0%
lyn-163 trial therapeutics malaria

Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 5.59% | O: -1.24% H: 0.71% C: -0.87%
trodelvy phase 3

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| Email alert Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer

Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Published: 2022-06-03 (Crawled : 22:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 3.46% | O: -2.01% H: 0.0% C: 0.0%
yescarta t-cell therapy

Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Published: 2022-06-03 (Crawled : 12:20) - globenewswire.com
CELU | News F | $3.09 -3.74% -3.88% 24K

| -68.38% | O: 1.52% H: 7.43% C: 4.53%
ABBV | $166.41 1.06% 0.0% 5.5M

Health Technology

| 13.15% | O: 0.54% H: 0.99% C: 0.29%
SNGX | $0.4233 -2.76% -2.83% 1M

Health Technology

| -18.26% | O: -3.4% H: 7.67% C: -1.65%
KURA | $17.55 -0.74% -0.74% 1.3M

Health Technology

| 35.31% | O: 1.09% H: 2.08% C: 0.97%
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 3.46% | O: -2.01% H: 0.0% C: 0.0%
CTIC | $9.09 0.05% 11M

Health Technology

| 52.35% | O: 1.01% H: 2.9% C: -4.64%
CALT | $17.65 -2.4% 4K

Health Technology

| -7.69% | O: 1.57% H: 0.0% C: -1.3%
AMGN | $269.03 2.39% 2.33% 3.4M

Health Technology

| 4.83% | O: -1.43% H: 0.0% C: 0.0%

Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
Published: 2022-06-03 (Crawled : 12:00) - biospace.com/
HOOK | $0.7317 -4.34% -4.54% 420K

Health Technology

| -55.29% | O: 0.59% H: 0.0% C: 0.0%
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 3.46% | O: -2.01% H: 0.0% C: 0.0%
preclinical hiv symposium pre-clinical vaccine

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
Published: 2022-06-02 (Crawled : 16:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 3.29% | O: -0.17% H: 0.0% C: 0.0%
sciences

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
Published: 2022-05-24 (Crawled : 01:00) - biospace.com/
KODK | $4.62 0.22% 0.65% 540K

Electronic Technology

| 5.07% | O: -2.76% H: 0.0% C: 0.0%
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 5.09% | O: 0.27% H: 0.0% C: 0.0%
CWBR | $0.9003 -11.88% 360

Health Technology

| 344.78% | O: 0.17% H: 5.38% C: -0.17%

Second Genome Presents New Data at Digestive Disease Week (DDW) 2022 Demonstrating that SG-5-00455, a Potential First-in-Class Precision Therapeutic, Improves Epithelial Barrier Function and Promotes Mucosal Healing in Inflammatory Bowel Disease
Published: 2022-05-24 (Crawled : 20:00) - prnewswire.com
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 4.81% | O: 0.97% H: 1.15% C: 0.87%
disease week potential

Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
Published: 2022-05-16 (Crawled : 12:00) - biospace.com/
CRM S | $270.37 -0.57% -0.06% 4.9M

Technology Services

| 68.82% | O: 0.69% H: 0.0% C: 0.0%
GILD | $66.77 0.92% 0.91% 11M

Health Technology

| 6.87% | O: -0.37% H: 0.59% C: -0.21%
GOOGL | News S | $154.08 -1.24% -1.25% 32M

Technology Services

| -93.19% | O: 0.93% H: 0.0% C: 0.0%
GOOG | News S | $155.7 -1.12% -1.13% 20M

Technology Services

| -93.14% | O: 1.57% H: 0.0% C: 0.0%
therapeutics

BioSpace Movers & Shakers: Singular Genomics, Marengo, Ventyx, Caribou and More
Published: 2022-05-13 (Crawled : 13:20) - biospace.com/
LH M | $201.48 1.02% 0.0% 770K

Health Services